You are here: Industry Insights > Eisai

News List

Eisai, Dementia Research Institute join forces for research pharmatimes
May 09, 2019
Eisai and the UK Dementia Research Institute (UK DRI) have announced the launch of a joint post-doctoral programme to support the advancement of novel dementia research.
Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs biospace
May 05, 2019
The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
Eisai acquires rights to lemborexant from Purdue Pharma pharmaceutical-technology
May 05, 2019
Eisai has bought the rights to investigational drug lemborexant from Purdue Pharma, ending a global development and commercialisation alliance signed in 2015.
Eisai selected as a Competitive IT Strategy Company 2019 biospectrumasia
April 25, 2019
The aim of the Competitive IT Strategy Company program is to introduce companies as attractive companies to investors who emphasize improving corporate value over the mid- to long-term and to promote companies' Competitive IT Strategies.
Japan grants Sakigake designation to Eisai’s novel FGFR biospectrumasia
April 08, 2019
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan.
Eisai starts Phase III clinical trial for Alzheimer's drug biospectrumasia
March 25, 2019
Clarity AD is a global placebo-controlled, double-blind, parallel-group……
Eisai, Biogen to advance Alzheimer's drug BAN2401 in Phase III testing following failure of aducanumab firstwordpharma
March 23, 2019
Eisai announced Friday that a Phase III trial has been initiated for the anti-amyloid beta protofibril antibody BAN2401……
Eisai to present latest research on Alzheimer's Disease / Dementia Pipeline biospectrumasia
March 23, 2019
Eisai Co., Ltd. announced that a total of seven presentations highlighting the latest data on its Alzheimer's disease/dementia pipeline……
Biogen, Eisai scrap late-stage studies of aducanumab in Alzheimer's disease as deemed unlikely to hit main goals firstwordpharma
March 21, 2019
Biogen and Eisai said Thursday that Phase III studies of the experimental anti-amyloid beta antibody aducanumab ……
Eisai and ImFDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia pharmafocusasia
March 12, 2019
Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page